GCG and metabolic dysfunction-associated steatohepatitis: Dual receptor agonism approaches are also showing promise in phase 2 trials of MASH with both Tirzepatide (a dual GLP1/GIP agonist) and Survodutide (a dual GLP1/Glucagon receptor agonist) meeting their primary end-points of remitting steatohepatitis without worsening of fibrosis and improvement in fibrosis stage of ≥ 1 grade without worsening of steatohepatitis when compared with placebo [53, 54].